Quidel Corporation (QDEL) fair value: what the stock is really worth
We calculate from audited financials what Quidel Corporation is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Sep 21, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Quidel Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 21, 2026.
How to read this chart
60‑month range $9.96 – $174.59 · fair‑value band $16.77 – $43.71 · the $10.34 price screens below the $31.02 fair value. Dashed = 300-day average. As of Sep 21, 2026.
Follow Quidel in your weekly email
Every Wednesday you see whether Quidel is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Show more
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
Stock analysis
Quidel Corporation (QDEL) currently trades at $10.34, while our model-based Fair Value estimate is $31.02, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $16.77 (bear) to $43.71 (bull), the price of $10.34 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Quidel Corporation reported revenue of $2.7B in FY2025 versus $1.7B in FY2021, a compound +12.6%/yr. Reported net income was −$1.1B in FY2025.
Key figures
Market cap $932M · P/S ratio 0.35 · EPS (TTM) $−17.85 · Net margin −41.5% · Return on equity −50.0% · Return on assets (EBIT) 0.4% · Operating margin −4.1% · Revenue (TTM) $2.7B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 71% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 200%, QDEL screens cheaper than that median.
Fair Value models
Bear $16.77Fair Value $31.02Bull $43.71
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.22/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−1.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Start year 2020 (pandemic). Over 10 years: +30.1% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
63.8% (2020) → −33.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside+200% · Top 25%
Profitability
Return on assets1% · Below median
Net margin (TTM)−46% · Bottom 25%
Operating margin (TTM)−4% · Below median
Growth and dividend
Revenue growth−11% · Bottom 25%
Balance sheet
Debt / equity1.29× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.49× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Quidel Corporation Fair Value". https://www.fairvalue-calculator.com/stock/QDEL
Frequently asked questions
Is Quidel Corporation (QDEL) overvalued or undervalued?
As of Sep 21, 2026, our model estimates a fair value of $31.02 versus a price of $10.34, about +200% upside (undervalued).
What is the fair value of QDEL?
Our model-based fair value for Quidel Corporation is $31.02 (as of Sep 21, 2026), built from audited fundamentals. The current price: $10.34.
What is the quality score of QDEL?
Quidel Corporation has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Quidel Corporation (QDEL)?
Our model-based price target is the fair value of $31.02 (as of Sep 21, 2026) from 1 valuation models. Cautious scenario $16.77, optimistic scenario $43.71. It is a calculation from audited fundamentals, not an analyst target.
What is the Quidel Corporation stock forecast for 2026?
Our models put fair value at $31.02, about +200% upside versus a price of $10.34 (undervalued). Cautious scenario $16.77, optimistic scenario $43.71. The calculation is refreshed regularly with new filings.
What is the revenue of Quidel Corporation (QDEL)?
Quidel Corporation reported trailing-twelve-month revenue of about $2.7B (latest available figure, as of Sep 21, 2026).
What is the intrinsic value of Quidel Corporation (QDEL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Quidel Corporation it is $31.02 per share (as of Sep 21, 2026), against a price of $10.34. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Quidel Corporation stock overvalued or undervalued in 2026?
As of Sep 21, 2026, QDEL trades below its calculated fair value: price $10.34, fair value $31.02, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of QDEL?
No. The price is what the market pays today ($10.34); the fair value is what the company's own numbers justify ($31.02). For Quidel Corporation the two are $20.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Quidel Corporation worth?
The market values Quidel Corporation at about $932M (market capitalisation, as of Sep 21, 2026). Per share that is $10.34; our models calculate a fair value of $31.02 per share.
What do the bullish and bearish scenarios say about QDEL?
Our models span a range for Quidel Corporation: cautious scenario $16.77, base $31.02, optimistic $43.71 per share (as of Sep 21, 2026, price $10.34). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of QDEL?
The PEG ratio of Quidel Corporation is 2.06 (P/E divided by earnings growth, as of Sep 21, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Quidel Corporation (QDEL)?
Balance-sheet figures for Quidel Corporation (as of Sep 21, 2026): return on equity −50.0%, debt of 1.29 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is QDEL from its 52-week high?
Quidel Corporation trades at $10.34, about 71% below its 52-week high of $35.38 and 4% above the low of $9.96 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $31.02 is for.
Which stocks are comparable to Quidel Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Quidel Corporation stock attractive at the current price?
The data as of Sep 21, 2026: price $10.34, calculated fair value $31.02 (+200%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of QDEL calculated?
We run Quidel Corporation through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $31.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Quidel Corporation currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Quidel Corporation (QDEL)?
The closing price on Sep 23, 2026 was $10.34. Our model-based fair value is $31.02, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Quidel Corporation right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($16.77). The market is more pessimistic than our downside scenario. The model range is unusually wide ($16.77 to $43.71). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Quidel Corporation
How large is the market capitalisation of Quidel Corporation (QDEL)?
The market capitalisation of Quidel Corporation is $932M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Quidel Corporation (QDEL)?
The price-to-sales ratio of Quidel Corporation is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Quidel Corporation (QDEL)?
Earnings per share at Quidel Corporation are $−17.85. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Quidel Corporation (QDEL)?
The net margin of Quidel Corporation is −41.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Quidel Corporation (QDEL)?
The return on equity (ROE) of Quidel Corporation is −50.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Quidel Corporation (QDEL)?
On an EBIT basis the return on assets of Quidel Corporation is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Quidel Corporation (QDEL)?
The operating margin of Quidel Corporation is −4.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Quidel Corporation (QDEL)?
Revenue at Quidel Corporation is growing −10.5% versus a year earlier (3y avg −5.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Quidel Corporation (QDEL)?
Earnings per share at Quidel Corporation are growing −77.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Quidel Corporation (QDEL) generate?
The free cash flow of Quidel Corporation is −$83.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Quidel Corporation (QDEL) carry?
The net debt of Quidel Corporation is $2.7B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Quidel Corporation in the live analysis
One click puts Quidel Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 21, 2026